Tidal Investments LLC Buys 22,804 Shares of Artivion, Inc. (NYSE:AORT)

Tidal Investments LLC grew its stake in shares of Artivion, Inc. (NYSE:AORT) by 14.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 179,806 shares of the company’s stock after buying an additional 22,804 shares during the period. Tidal Investments LLC’s holdings in Artivion were worth $5,141,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of AORT. Barclays PLC increased its position in shares of Artivion by 346.3% during the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock valued at $1,888,000 after buying an additional 54,996 shares during the period. Franklin Resources Inc. increased its position in shares of Artivion by 14.4% during the third quarter. Franklin Resources Inc. now owns 21,107 shares of the company’s stock valued at $553,000 after buying an additional 2,663 shares during the period. JPMorgan Chase & Co. increased its position in shares of Artivion by 394.9% during the third quarter. JPMorgan Chase & Co. now owns 97,903 shares of the company’s stock valued at $2,606,000 after buying an additional 78,120 shares during the period. KBC Group NV increased its position in shares of Artivion by 80.4% in the fourth quarter. KBC Group NV now owns 2,813 shares of the company’s stock worth $80,000 after purchasing an additional 1,254 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of Artivion in the fourth quarter worth approximately $39,000. 86.37% of the stock is currently owned by institutional investors.

Artivion Stock Down 2.1%

Shares of NYSE AORT opened at $29.10 on Wednesday. Artivion, Inc. has a one year low of $21.97 and a one year high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The firm’s 50 day simple moving average is $24.87 and its two-hundred day simple moving average is $27.34. The stock has a market capitalization of $1.24 billion, a P/E ratio of -1,455.00 and a beta of 1.54.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $98.98 million for the quarter, compared to the consensus estimate of $94.81 million. As a group, analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insider Buying and Selling at Artivion

In other news, SVP Marshall S. Stanton sold 10,548 shares of the firm’s stock in a transaction that occurred on Friday, May 9th. The shares were sold at an average price of $29.13, for a total value of $307,263.24. Following the transaction, the senior vice president now owns 105,332 shares in the company, valued at approximately $3,068,321.16. This trade represents a 9.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Jean F. Holloway sold 5,335 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the transaction, the senior vice president now owns 149,799 shares in the company, valued at $4,091,010.69. This represents a 3.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 101,347 shares of company stock worth $2,663,486 over the last ninety days. Insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on AORT. JMP Securities restated a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research report on Tuesday, May 6th. Citizens Jmp upgraded shares of Artivion to a “strong-buy” rating in a research report on Tuesday, May 6th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of Artivion in a research report on Tuesday, May 6th. Finally, Stifel Nicolaus decreased their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.